Piboserod

DB04873InvestigationalSmall molecule

Piboserod (SB 207266) is a selective 5-HT(4) receptor antagonist.

Mechanism: Piboserod appears to act as a specific antagonist of one of the receptors for 5-hydroxytryptamine, the 5-HT4 receptor. The 5-HT4 receptor antagonists are thought to antagonize both the ability of serotonin to sensitize the peristaltic reflex and 5-HT-induced defecation, at least in animal studies. As 5-HT4 receptors are present in human atrial cells and when stimulated may cause atrial arrhythmias, piboserod was under investigation in clinical trials for atrial fibrillation.
Curator reviewed
Primary indication: For the treatment of atrial fibrillation and irritable bowel syndrome (IBS).Curator reviewed
Formula / weight: C₂₂H₃₁N₃O₂ · 369.5004 g/mol (avg)
Code names: 207266 · SB-207266

Resolves to

Compound

Structure

InChIKeyKVCSJPATKXABRQ-UHFFFAOYSA-NSMILESCCCCN1CCC(CNC(=O)C2=C3OCCCN3C3=CC=CC=C23)CC1

Targets

What you can answer from here — as of August 26, 2024

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Piboserod, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.